Cargando…

Efficacy of Fumaric Acid Esters in the R6/2 and YAC128 Models of Huntington's Disease

Huntington's disease (HD) is an autosomal dominantly inherited progressive neurodegenerative disease. The exact sequel of events finally resulting in neurodegeneration is only partially understood and there is no established protective treatment so far. Some lines of evidence speak for the cont...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ellrichmann, Gisa, Petrasch-Parwez, Elisabeth, Lee, De-Hyung, Reick, Christiane, Arning, Larissa, Saft, Carsten, Gold, Ralf, Linker, Ralf A.
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3031519/ https://www.ncbi.nlm.nih.gov/pubmed/21297955 http://dx.doi.org/10.1371/journal.pone.0016172

Ejemplares similares

The Role of the Immune System in Huntington's Disease
por: Ellrichmann, Gisa, et al.
Publicado: (2013)

Increase of angiotensin II type 1 receptor auto-antibodies in Huntington’s disease
por: Lee, De-Hyung, et al.
Publicado: (2014)

Mechanisms of Oxidative Damage in Multiple Sclerosis and Neurodegenerative Diseases: Therapeutic Modulation via Fumaric Acid Esters
por: Lee, De-Hyung, et al.
Publicado: (2012)

Author Correction: Laquinimod treatment in the R6/2 mouse model
por: Ellrichmann, Gisa, et al.
Publicado: (2019)

Laquinimod treatment in the R6/2 mouse model
por: Ellrichmann, Gisa, et al.
Publicado: (2017)

Antidepressant Effects of Probucol on Early-Symptomatic YAC128 Transgenic Mice for Huntington's Disease
por: de Paula Nascimento-Castro, Cristine, et al.
Publicado: (2018)

Temporal Characterization of Behavioral and Hippocampal Dysfunction in the YAC128 Mouse Model of Huntington’s Disease
por: de Paula Nascimento-Castro, Cristine, et al.
Publicado: (2022)

Positive effect of immunomodulatory therapies on disease progression in Huntington’s disease? Data from a real-world cohort
por: Achenbach, Jannis, et al.
Publicado: (2022)

Transplantation of patient-derived adipose stem cells in YAC128 Huntington's disease transgenic mice
por: Im, Wooseok, et al.
Publicado: (2010)

Neonatal Iron Supplementation Induces Striatal Atrophy in Female YAC128 Huntington’s Disease Mice
por: Berggren, Kiersten L., et al.
Publicado: (2016)

Age-related mitochondrial alterations in brain and skeletal muscle of the YAC128 model of Huntington disease
por: Bečanović, Kristina, et al.
Publicado: (2021)

Beyond Motor Deficits: Environmental Enrichment Mitigates Huntington’s Disease Effects in YAC128 Mice
por: Plácido, Evelini, et al.
Publicado: (2023)

Structural and molecular myelination deficits occur prior to neuronal loss in the YAC128 and BACHD models of Huntington disease
por: Teo, Roy Tang Yi, et al.
Publicado: (2016)

Mice lacking caspase-2 are protected from behavioral changes, but not pathology, in the YAC128 model of Huntington disease
por: Carroll, Jeffrey B, et al.
Publicado: (2011)

Author Correction: Age-related mitochondrial alterations in brain and skeletal muscle of the YAC128 model of Huntington disease
por: Bečanović, Kristina, et al.
Publicado: (2021)

Constitutive activity of NF-kappa B in myeloid cells drives pathogenicity of monocytes and macrophages during autoimmune neuroinflammation
por: Ellrichmann, Gisa, et al.
Publicado: (2012)

Altering cortical input unmasks synaptic phenotypes in the YAC128 cortico-striatal co-culture model of Huntington disease
por: Schmidt, Mandi E., et al.
Publicado: (2018)

Neural stem cells derived from the developing forebrain of YAC128 mice exhibit pathological features of Huntington’s disease
por: Li, Endan, et al.
Publicado: (2020)

Error Processing in Huntington's Disease
por: Beste, Christian, et al.
Publicado: (2006)

PGC-1alpha as modifier of onset age in Huntington disease
por: Taherzadeh-Fard, Elahe, et al.
Publicado: (2009)

Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease
por: Garcia-Miralles, Marta, et al.
Publicado: (2016)

A CAG repeat-targeting artificial miRNA lowers the mutant huntingtin level in the YAC128 model of Huntington's disease
por: Kotowska-Zimmer, Anna, et al.
Publicado: (2022)

Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience
por: Schneider-Gold, Christiane, et al.
Publicado: (2017)

Fumaric Acid and its Esters: An Emerging Treatment for Multiple Sclerosis
por: Moharregh-Khiabani, D, et al.
Publicado: (2009)

Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease
por: Van Raamsdonk, Jeremy M, et al.
Publicado: (2006)

Differential Synaptic and Extrasynaptic Glutamate-Receptor Alterations in Striatal Medium-Sized Spiny Neurons of Aged YAC128 Huntington’s Disease Mice
por: Botelho, Eliã P., et al.
Publicado: (2014)

Role of Nuclear Factor (Erythroid-Derived 2)-Like 2 Signaling for Effects of Fumaric Acid Esters on Dendritic Cells
por: Hammer, Anna, et al.
Publicado: (2017)

Glutathione S-Transferase Ω 1 variation does not influence age at onset of Huntington's disease
por: Arning, Larissa, et al.
Publicado: (2004)

Peripheral CD19(+) B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders
por: Ellrichmann, Gisa, et al.
Publicado: (2018)

Correction: Differential Synaptic and Extrasynaptic Glutamate-Receptor Alterations in Striatal Medium-Sized Spiny Neurons of Aged YAC128 Huntington's Disease Mice
Publicado: (2017)

DAPK1 Promotes Extrasynaptic GluN2B Phosphorylation and Striatal Spine Instability in the YAC128 Mouse Model of Huntington Disease
por: Schmidt, Mandi E., et al.
Publicado: (2020)

Time Processing in Huntington's Disease: A Group-Control Study
por: Beste, Christian, et al.
Publicado: (2007)

Failure to confirm influence of Methyltetrahydrofolate reductase (MTHFR) polymorphisms on age at onset of Huntington disease
por: Hansen, Wiebke, et al.
Publicado: (2005)

In vivo Dopamine Efflux is Decreased in Striatum of both Fragment (R6/2) and Full-Length (YAC128) Transgenic Mouse Models of Huntington's Disease
por: Callahan, Joshua W., et al.
Publicado: (2011)

In Vivo Roles of a Patient-Derived Induced Pluripotent Stem Cell Line (HD72-iPSC) in the YAC128 Model of Huntington’s Disease
por: Jeon, Iksoo, et al.
Publicado: (2014)

Solid Lipid Curcumin Particles Protect Medium Spiny Neuronal Morphology, and Reduce Learning and Memory Deficits in the YAC128 Mouse Model of Huntington’s Disease
por: Gharaibeh, Abeer, et al.
Publicado: (2020)

Similar striatal gene expression profiles in the striatum of the YAC128 and HdhQ150 mouse models of Huntington’s disease are not reflected in mutant Huntingtin inclusion prevalence
por: Bayram-Weston, Zubeyde, et al.
Publicado: (2015)

Age at onset of Huntington disease is not modulated by the R72P variation in TP53 and the R196K variation in the gene coding for the human caspase activated DNase (hCAD)
por: Arning, Larissa, et al.
Publicado: (2005)

Insight into Metabolic (1)H-MRS Changes in Natalizumab Induced Progressive Multifocal Leukoencephalopathy Brain Lesions
por: Schneider, Ruth, et al.
Publicado: (2017)

No association between polymorphisms in the BDNF gene and age at onset in Huntington disease
por: Mai, Maren, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_43ljtavk9c0oo7asnahb2mm23k